Abstract:The corona virus (SARS-CoV-2) pandemic and the resulting long-term neurological complications in patients, known as long COVID, have renewed the interest in the correlation between viral infections and neurodegenerative brain disorders. While many viruses can reach the central nervous system (CNS) causing acute or chronic infections (such as herpes simplex virus 1, HSV-1), the lack of a clear mechanistic link between viruses and protein aggregation into amyloids, a characteristic of several neurodegenerative diseases, has rendered such a connection elusive. Recently, we showed that viruses can induce aggregation of purified amyloidogenic proteins via the direct physicochemical mechanism of heterogenous nucleation (HEN). In the current study, we show that the incubation of HSV-1 and SARS-CoV-2 with human cerebrospinal fluid (CSF) leads to the amyloid aggregation of several proteins known to be involved in neurodegenerative diseases, such as: APLP1 (amyloid beta precursor like protein 1), ApoE, clusterin, α2-macroglobulin, PGK-1 (phosphoglycerate kinase 1), ceruloplasmin, nucleolin, 14-3-3, transthyretin and vitronectin. Importantly, UV-inactivation of SARS-CoV-2 does not affect its ability to induce amyloid aggregation, as amyloid formation is dependent on viral surface catalysis via HEN and not its ability to replicate. Additionally, viral amyloid induction led to a dramatic drop in the soluble protein concentration in the CSF. Our results show that viruses can physically induce amyloid aggregation of proteins in human CSF and result in soluble protein depletion, and thus providing a potential mechanism that may account for the association between persistent and latent/reactivating brain infections and neurodegenerative diseases.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to explore how SARS-CoV-2 and HSV-1 viruses induce amyloid protein aggregation in human cerebrospinal fluid (CSF) and lead to a significant reduction in soluble proteins. Specifically, the researchers hope to experimentally verify the following issues: 1. **Relationship between viruses and neurodegenerative diseases**: For a long time, viruses have been thought to be potentially related to neurodegenerative diseases, but there has been a lack of clear mechanistic explanations. This paper attempts to experimentally demonstrate that viruses can directly induce amyloid protein aggregation, thereby providing mechanistic evidence for this relationship. 2. **Mechanism of virus-induced amyloid protein aggregation**: The researchers hope to reveal through experiments how viruses act as physical catalysts to induce amyloid protein aggregation through the heterogeneous nucleation (HEN) mechanism. In particular, they want to demonstrate that this aggregation is not dependent on the virus's replication ability but is driven by the physical properties of the virus surface. 3. **Impact of amyloid protein aggregation on cerebrospinal fluid**: The researchers also hope to understand whether virus-induced amyloid protein aggregation leads to a significant reduction in soluble proteins in the cerebrospinal fluid and whether this reduction could be a potential mechanism for the neurological symptoms observed after viral infection. ### Research Background - **SARS-CoV-2 and Long COVID**: The COVID-19 pandemic has not only led to high mortality rates globally but also caused a large number of patients to experience long-term neurological symptoms such as fatigue, headaches, and "brain fog." - **Viruses and neurodegenerative diseases**: Other viruses, such as herpes simplex virus type 1 (HSV-1) and influenza virus, have also been found to be associated with neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD). - **Early studies on virus-induced amyloid protein aggregation**: Early studies have shown that UV-inactivated viruses can still induce amyloid protein aggregation, suggesting that viruses may induce protein aggregation through non-nucleic acid-dependent mechanisms. ### Main Findings - **Virus-induced amyloid protein aggregation**: The researchers found that HSV-1 and UV-inactivated SARS-CoV-2 viruses can induce the formation of amyloid aggregates of various proteins known to be associated with neurodegenerative diseases in human cerebrospinal fluid. - **Proteomics analysis**: Through mass spectrometry analysis, the researchers identified various proteins enriched in virus-induced amyloid aggregates, which had previously been found in amyloid plaques of AD patients. - **Reduction in soluble proteins**: Experimental results showed that virus-induced amyloid protein aggregation led to a significant reduction in soluble proteins in the cerebrospinal fluid, which could be an important mechanism leading to neurodegenerative diseases. ### Significance - **Mechanistic evidence**: This paper provides mechanistic evidence that viruses can directly induce amyloid protein aggregation through a physical catalytic mechanism, offering a new perspective on the link between viruses and neurodegenerative diseases. - **Potential mechanism**: The research results suggest that virus-induced amyloid protein aggregation may lead to a significant reduction in soluble proteins in the cerebrospinal fluid, which could be a potential mechanism for the neurological symptoms observed after viral infection. - **Future research directions**: Further research can explore changes in protein levels in the cerebrospinal fluid after viral infection to better understand this potential pathophysiological mechanism.

SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein Depletion

Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19

Cell invasive amyloid assemblies from SARS-CoV-2 peptides can form multiple polymorphs with varying neurotoxicity

HSV-1 and Cellular miRNAs in CSF-Derived Exosomes as Diagnostically Relevant Biomarkers for Neuroinflammation

SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation

Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses

Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients

SARS and synapses

Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid--associated pathology in APP/PS1 mouse model of Alzheimer's disease

Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes

The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation

SARS-CoV-2 infection in hiPSC-derived neurons is cathepsin-dependent and causes accumulation of HIF1alpha and phosphorylated tau

Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders

Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer's Disease

Microfluidic Isolation of Neuronal-Enriched Extracellular Vesicles Shows Distinct and Common Neurological Proteins in Long COVID, HIV Infection and Alzheimer's Disease

Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis

Viral Involvement in Alzheimer’s Disease

The emerging mechanism behind viral infections and extracellular vesicles hypotheses leading to neuroinflammation and Alzheimer's disease pathology

From Viral Infections to Alzheimer's Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics

Neuropathological findings in Down syndrome, Alzheimer's disease and control patients with and without SARS-COV-2: preliminary findings